Chartered Trade Mark Attorney, Alexandra Nott explores some of the reasons that trade mark protection remains crucial in today’s business environment.
READ MORE
In this insight, Biotechnology partner Kit Wilkins reviews the US Supreme Court’s decision to Consider “Skinny Labels” in Generic Drug Patent Dispute. The decision could result in significant implications of generic medicines in the US.
READ MORE
In this insight, Holly Rocliffe from Dehns Biotechnology group explores the recently handed down decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161[1], in which the Full Court of the Federal Court of Australia (Full Court) has ruled that patent term extension (PTE) is only available for patents which claim an active pharmaceutical ingredient (API).
READ MORE
The first decision from the UPC on sufficiency — handed down in the Amgen v. Sanofi case — provides the first clear guidance on how the court will address whether a patent’s disclosure is sufficient.
READ MORE
In this insight, Dehns Partner Rob Jackson and Conor Wilman from our Technology, Software and Engineering group explore the UPC’s Court of Appeal recent issues of two important decisions about how it will assess inventive step in patent cases.
READ MORE
The UK Intellectual Property Office (UKIPO) is consulting on possible changes to the UK design framework with the aims of improving design validity, simplifying the regime, and protecting emerging forms of design.
READ MORE
The G1/23 ruling from the European Patent Office marked a pivotal shift in how marketed products are treated as prior art, redefining the principles of reproducibility and disclosure across Europe. Dehns has collaborated with international patent experts to provide a global perspective on the ruling.
READ MORE
This decision concerned an application for provisional measures, in particular an anti-anti-suit injunction (‘AASI’), by Avago Technologies International Sales Pte. Limited against the defendant Realtek Semiconductor Corporation
READ MORE
Plant Variety Rights (PVRs), also known as Plant Breeders’ Rights (PBRs), are an important form of intellectual property for plant breeders seeking protection for their investment in the generation of a new variety of plant. As many patent offices, including the European Patent Office (EPO) and UK Intellectual Property Office (UKIPO), have provisions that exclude individual plant varieties from patent protection, PVRs represent a valuable asset for plant breeders in many countries.
Methods for treatment of the human or animal body by therapy (or surgery) are excluded from patent protection at the EPO under Article 53(c) EPC. The purpose of the exclusion is to avoid restricting the activities of medical and veterinary practitioners. In contrast, purely non-therapeutic methods of treatment, e.g. purely cosmetic methods, are permitted.
On face value, the EPO’s approach seems clear and navigable. However, in practice the waters are murkier.
In this episode of The IP Podcast, Dehns Partner Mark Bell looks at a major topic in the IP world, and certainly the biggest and most significant change to the European Patent system for nearly 50 years – the introduction of the Unified Patent Court and the Unitary Patent.
Cadbury finally hits a purple patch: Paul Harris, Head of Litigation at Dehns, provides a case analysis of Nestlé v Cadbury.
In this article, Joseph Letang, Partner in the Dehns Trade Marks Group, warns against claiming rights in descriptive terms.
This webinar covers filing priority applications, inventors and owners, the international (PCT) patent application process and filing foreign patent applications.
In the first episode of Season 2 of The IP Podcast, Dehns Partner Tim Wilson takes a look at NFTs and the main IP issues surrounding them.
The Genetic Technology Bill – announced on the 25 May 2022 by the Department for Environment, Food and Rural Affairs (Defra) – aims to take advantage of the UK’s post-Brexit position and relax the regulation around precision breeding.
When justice needs to be seen to be done: Paul Harris, Head of Litigation at Dehns, provides a case analysis of ABP Technology Ltd v Voyetra Turtle Beach.
Paul Harris, Head of Litigation at Dehns, discusses a trial of an account of profits.
Subscribe here for updates on IP news, events and webinars.
|